Analysis by thyroid cancer type across all studies (including both primary and supplementary datasets) revealed a greater focus on medullary thyroid cancer (MTC) (n = 11) for selective RET inhibitors. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.